NANOX
21.8.2020 13:46:08 CEST | Business Wire | Press release
NANO-X IMAGING LTD (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today the pricing of its initial public offering of 9,178,744 ordinary shares at a price to the public of US$18 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nanox, are expected to be US$165.2 million. In addition, Nanox has granted the underwriters a 30-day option to purchase up to an additional 1,376,812 ordinary shares at the initial public offering price, less underwriting discounts and commissions. All of the shares are being offered by Nanox.
The shares are expected to begin trading on the Nasdaq Global Market under the ticker symbol “NNOX” on August 21, 2020. The offering is expected to close on August 25, 2020, subject to customary closing conditions.
Cantor Fitzgerald & Co., Oppenheimer & Co. Inc., Berenberg and CIBC Capital Markets are acting as joint book-runners. National Securities Corporation is acting as co-manager for the offering.
A registration statement, including a prospectus, on Form F-1 relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. The offering will be made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained by contacting: Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com , Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com , Berenberg Capital Markets, LLC, Attention: Equity Capital Markets, 1251 Avenue of the Americas, 53rd Floor, New York, NY 10020, telephone: (646) 949-9000, or CIBC Capital Markets, 425 Lexington Avenue, 5th floor, New York, NY, by telephone at (800) 282-0822, or by email at useprospectus@cibc.com .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200821005266/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights5.8.2026 12:30:00 CEST | Press release
Data from two positive Phase 3 trials demonstrated rapid onset of effect and durable benefit through at least 6 months, further validating COMP360’s potential to establish a new standard of care in TRD COMP360 has a highly differentiated clinical profile and is expected to be a blockbuster opportunity, if approved Rolling NDA submission and initial review underway and final submission expected to be completed in Q4 Commercial launch expected in first half of 2027 COMP360 expected to fit seamlessly into current treatment infrastructure Late-stage PTSD trial underway Strong cash position of $433 million at the end of second quarter, providing cash well beyond launch and into 2028 Compass management will host a conference call on August 5 at 8:00 am ET Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the second quarter and first half 2026 financial results and business highlights
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates5.8.2026 12:00:00 CEST | Press release
Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior yearDiluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarterRaised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “These strong second-quarter results underscore our continued growth as a global oncology leader. Our foundational hematology franchise, led by BRUKINSA, continues to gain momentum as we advance one of the industry’s deepest and most
Tecnotree Delivers Double-Digit Profit Growth and Accelerated Deployment Momentum in H1 20265.8.2026 11:11:00 CEST | Press release
Tecnotree, a global leader in AI-native Digital Business Support Systems (BSS) and digital platform solutions for the telecommunications industry, today announced its financial results for the first half of 2026. The company delivered growth across every principal financial measure, expanded operating margin by 800 basis points, and converted a record order book into deployment at pace, with eight go-lives completed across the North America, Africa and the Middle East. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805406933/en/ Tecnotree Delivers Double-Digit Profit Growth and Accelerated Deployment Momentum in H1 2026 First Half (January – June 2026) Net sales of EUR 36.8 million (EUR 34.2 million), up 7.5% year-on-year; in constant currency, EUR 37.6 million, up 10.0% year-on-year. Operating result (EBIT) of EUR 13.2 million (EUR 9.6 million), up 38.1% year-on-year. Operating margin of 36.0% (28.0%), up 800 bps year-on
Ekovolt Welcomes Éric Scotto, Co-Founder of Akuo Energy, as a Shareholder, and Rebrands as Pont Digital Infrastructure5.8.2026 10:00:00 CEST | Press release
Ekovolt, a holding company focused on the development and investment in next-generation data centre infrastructure, and co-owner of Voltekko, a Southern European data centre development platform, today announces two milestones: Éric Scotto — co-founder and former President of Akuo Energy, a pioneering figure in the French and international energy transition — becoming a shareholder, and the company’s rebranding as Pont Digital Infrastructure. Éric Scotto, an iconic figure in French renewable energy, joins the company as a shareholder, bringing recognised expertise in developing, financing and structuring long-term sustainable infrastructure projects. After an early career in information technology and finance, Éric Scotto moved into renewable energy in 2003. He founded Perfect Wind and developed one of the first large-scale wind farms in France (57 MW) in partnership with General Electric — with operations also in Poland and Turkey — before selling the company to Iberdrola in 2006. In
Bending Spoons opens office in Madrid, betting on a promising pool of tech talent5.8.2026 09:00:00 CEST | Press release
Bending Spoons, the technology company behind products such as WeTransfer and Meetup, has opened an office in Madrid. The decision is underpinned by Spain’s strong talent pool, fuelled by excellent universities, and by Madrid’s international appeal and its quality of life. “We’re impressed by the talent we’ve seen in Spain. This year, we’ve received around 10,000 Spain-based applicants every month, and many of them perform among the very best candidates in our selection process. The calibre of education offered by Spanish universities is particularly high, and over the next few years we’re hoping to grow our team in Madrid into the hundreds,” says Andrea Maiorana, talent data lead. Located in the Recoletos area, the office is the company’s third European base, following the Milan headquarters and the recently opened London branch. The office is in one of the city's most coveted locations, within walking distance of Retiro Park and the Prado Museum. For new hires relocating to Madrid, B
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom